An Open Label Trial of ALD403 (Eptinezumab) in Chronic Migraine
Public ClinicalTrials.gov record NCT02985398. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open Label Phase 3 Trial to Evaluate the Safety of ALD403 Administered Intravenously in Patients With Chronic Migraines
Study identification
- NCT ID
- NCT02985398
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Alder Biopharmaceuticals, Inc.
- Industry
- Enrollment
- 128 participants
Conditions and interventions
Conditions
Interventions
- ALD403 (Eptinezumab) Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2016
- Primary completion
- Mar 31, 2018
- Completion
- Feb 28, 2019
- Last update posted
- Apr 20, 2020
2016 – 2019
United States locations
- U.S. sites
- 20
- U.S. states
- 12
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | San Diego | California | 92108 | — |
| Research Site | Santa Monica | California | 90404 | — |
| Research Site | Colorado Springs | Colorado | 80918 | — |
| Research Site | Bradenton | Florida | 34201 | — |
| Research Site | DeLand | Florida | 32720 | — |
| Massachusetts | Miami | Florida | 33125 | — |
| Research Site | Tampa | Florida | 33634 | — |
| Research Site | Winter Haven | Florida | 33880 | — |
| Research Site | Prairie Village | Kansas | 66206 | — |
| Massachusetts | Boston | Massachusetts | 02131 | — |
| Research Site | North Attleboro | Massachusetts | 02760 | — |
| 02481 | Wellesley | Massachusetts | 02481 | — |
| Research Site | Minneapolis | Minnesota | 55402 | — |
| Research Site | Brooklyn | New York | 11229 | — |
| Research Site | Rochester | New York | 14609 | — |
| Research Site | Dayton | Ohio | 45432 | — |
| Research Site | Mt. Pleasant | South Carolina | 29464 | — |
| Research Site | Chattanooga | Tennessee | 37421 | — |
| Research Site | Fort Worth | Texas | 76104 | — |
| Research Site | Bellevue | Washington | 98007 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02985398, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 20, 2020 · Synced May 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02985398 live on ClinicalTrials.gov.